10.33 0.00 (0.00%)
After hours: 5:53PM EDT
|Bid||10.26 x 4000|
|Ask||11.27 x 1800|
|Day's Range||10.27 - 10.62|
|52 Week Range||2.23 - 12.22|
|Beta (3Y Monthly)||2.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.75|
ArQule, Inc. (ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,387,500 shares at the public offering price of $9.75 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by ArQule to 10,637,500 shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and estimated expenses of the offering payable by ArQule, to approximately $103.7 million. SVB Leerink and RBC Capital Markets acted as joint bookrunning managers for the offering.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...
ArQule, Inc. (ARQL) today announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 per share. ArQule has granted the underwriters a 30-day option to purchase up to an additional 1,387,500 shares of its common stock. The gross proceeds to ArQule from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $90.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by ArQule.
ArQule, Inc. (ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, ArQule expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by ArQule.
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
ArQule, Inc. (ARQL) today announced that Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 at 8:00 a.m. ET at the The Mandarin Oriental New York, New York. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
Biotech sector exchange traded funds rallied Monday after Pfizer (NYSE: PFE) said it would acquire Array Biopharma Inc. (NasdaqGS: ARRY) in a $10.6 billion deal to bolster its portfolio of cancer fighting ...
Close on the heels of a 30% rally Friday on the back of positive results from an early stage study of its leukemia drug candidate, ArQule announced preliminary results from a Phase 1/2 study of its pan-AKT inhibitor miransertib, or ARQ 092, in patients with PIK3CA-related Overgrowth Spectrum, or PROS, and Proteus syndrome, or PS. The data was presented at the European Society of Human Genetics Conference in Gothenburg, Sweden. The recommended initial dose for the registrational study was defined as a 15mg/square meter once-daily dose, with a subsequent maximum dose increase to 25 mg/square meter.
ArQule, Inc. (ARQL) today announced preliminary results from the company’s phase 1/2 study of its pan-AKT inhibitor, miransertib (ARQ 092), in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the European Society of Human Genetics Conference in Gothenburg, Sweden.
For biotech stocks, the week was back loaded with multiple conferences scheduled for the later half of the week. Nevertheless, there were volatile moves in some low-float, thinly traded stocks. Looking ...
ArQule (NASDAQ:ARQL) began the day and ended the week with a bang as the company's latest blood cancer treatment has shown early signs of promise in helping patients with tumors heal.The Woburn, Mass.-based pharmaceutical business announced its preliminary data from a Phase 1 trial in regards to its investigational cancer drug ARQ 531. The company's early-stage trial is still ongoing, and it examined the effects of several different doses of the drug in 34 patients suffering from advanced chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), Richter's Transformation, Waldenstrom macroglobulinemia as well as other B-cell Non-Hodgkin lymphomas.ArQule's Phase 1 trials are designed to establish a recommended dose of a new drug for study for the Phase 2 trials. Researchers from the study looking at ARQ 531 said patients were fine at dosages of up to 65 milligrams once a day.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe drug displayed promising anti-tumor activity in some patients, according to the company. "We are now focused on finalizing the recommended Phase 2 dose and planning for the expansion of our clinical efforts with ARQ 531 into later stage trials across multiple indications as a single agent and as a combination therapy," said ArQule Chief Medical Officer Brian Schwartz in a statement.ARQL stock is soaring a whopping 32.6% following the company's news on Friday. This helped push the company's per share price to a 12-year high of $8.34. More From InvestorPlace * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Stocks to Buy for the Coming Recession * 7 High-Quality Cheap Stocks to Buy With $10 Compare Brokers The post ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results appeared first on InvestorPlace.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ArQule, Inc. (NASDAQ: ARQL ) shares were up ...
shares are up more than 35% Friday after the company announced positive phase 1 results from the trial of its orally bioavailable, potent and reversible dual inhibitor for patients with relapsed or refractory hematologic malignancies. "The profile of ARQ 531 continues to strengthen, and we are delighted to be able to demonstrate such compelling clinical activity at a well-tolerated dose in patients who have already exhausted available therapies," commented Dr. Brian Schwartz, Chief Medical Officer of ArQule. The phase 1 study is an open label, single arm dose escalation study with eight levels of dosage once a day in patients with relapsed or refractory chronic lymophcytic leukemia.
Shares of ArQule, Inc. (NASDAQ: ARQL ) are galloping toward a multiyear high in the wake of the presentation of a clinical trial readout. What Happened The small-cap biotech announced preliminary results ...